Tradestie Institutional Equity Comparison Engine

BGM vs INCR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INCR Overall Edge

INCR Captures Institutional Edge (4โ€“0 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Intercure Ltd. Ordinary Shares (INCR) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BGM trades at N/M Forward P/E with -23.4% operating margin (+69.8% YoY revenue) versus INCR at 6.2x Forward P/E and 0.0% operating margin (+23.9% YoY). In options structure, BGM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against INCR sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner INCR
BGM N/M vs INCR 6.2x Fwd P/E
Growth & Margin Winner INCR
Op Margin -23.4% vs 0.0% ยท YoY +69.8% vs +23.9%
Momentum & Technical Winner INCR
1Y -17.5% vs +136.7% ยท 52W Pos 74% vs 47%
Options & Structure Winner INCR
UNCLASSIFIED (N/A IV) vs BREAKDOWN (<1st %ile IV)
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
1M Return -21.57%
1Y Return -17.53%
Forward P/E N/M
Unified AI Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
INCR NASDAQ
Intercure Ltd. Ordinary Shares
Pharmaceutical Preparations
$3.24
-7.16% 1D
Market Cap $45.5M
1M Return -26.86%
1Y Return +136.67%
Forward P/E 6.2x
Unified AI Score
66.8 / 100 BUY
Tech 68.0 Fund 62.0 Flow 58.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BGM -17.53% INCR +136.67% Spread: +174.33 pp (INCR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BGM TTM Op. Margin: -23.4% INCR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs INCR. Trailing 12-month operating profitability (BGM -23.4% vs INCR 0.0%) and valuation multiples (BGM N/M vs INCR 6.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BGM (4) vs INCR (5)
Institutional Metric BGM INCR Criterion Row Winner
Market Capitalization Scale $108.6M $45.5M Larger Scale BGM
Trailing P/E Ratio Valuation N/M 6.2x Lower Multiple INCR
Forward P/E Ratio Valuation N/M 6.2x Lower Multiple INCR
Revenue Growth (YoY) Growth +69.8% +23.9% Higher Growth BGM
Operating Margin (TTM) Profitability -23.4% 0.0% Higher Margin INCR
Net Profit Margin Profitability -44.2% -13.2% Higher Margin INCR
Return on Equity (ROE) Capital Efficiency -7.4% -9.3% Higher ROE BGM
52-Week Range Position Momentum 74% ($0โ€“$11) 47% ($1โ€“$6) Stronger Trend BGM
Beta / 30D Volatility Risk Regime 3.69ฮฒ ยท 80% Vol 0.07ฮฒ ยท 80% Vol Lower Realized Risk Tie
Unified Institutional Score Composite Signal 59.6 / 100 (HOLD) 66.8 / 100 (BUY) Higher Composite INCR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BGM vs INCR Buy Guide
BGM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
INCR BREAKDOWN
59d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live INCR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BGM nor INCR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.